Article Text

Download PDFPDF

Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study
  1. M Rudwaleit1,
  2. E Rødevand2,
  3. P Holck3,
  4. J Vanhoof4,
  5. M Kron5,
  6. S Kary5,
  7. H Kupper5
  1. 1
    Charité University Medicine Berlin, Benjamin Franklin Campus, Berlin, Germany
  2. 2
    St Olavs Hospital, Trondheim, Norway
  3. 3
    Regionshospitalet Silkeborg, Silkeborg, Denmark
  4. 4
    University Hasselt, Hasselt, Belgium
  5. 5
    Abbott GmbH & Co KG, Ludwigshafen, Germany
  1. M Rudwaleit, Charité, Campus Benjamin Franklin Hospital, Medical Department I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany; martin.rudwaleit{at}


Objective: To evaluate the effect of adalimumab on the frequency of anterior uveitis (AU) flares in patients with active ankylosing spondylitis (AS).

Methods: We determined the history of ophthalmologist-diagnosed AU in 1250 patients with active AS who were enrolled in a multinational, open-label, uncontrolled clinical study of treatment with adalimumab, 40 mg every other week for up to 20 weeks. All AU flares were documented throughout the adalimumab treatment period plus 70 days. We compared the rates of AU flares per 100 patient years (PYs) reported during the year before adalimumab treatment with rates during adalimumab treatment, in total and by patient subgroups.

Results: The AU flare rates before adalimumab treatment were 15/100 PYs in all patients (n = 1250), 68.4/100 PYs in 274 patients with a history of AU flares, 176.9/100 PYs in 106 patients with a recent history of AU flares, 192.9/100 PYs in 28 patients with symptomatic AU at baseline and 129.1/100 PYs in 43 patients with a history of chronic uveitis. During adalimumab treatment, the rate of AU flares was reduced by 51% in all patients, by 58% in 274 patients with a history of AU, by 68% in 106 patients with a recent history of AU, by 50% in 28 patients with symptomatic AU at baseline and by 45% in 43 patients with chronic uveitis. AU flares during adalimumab treatment were predominantly mild. Two patients with periods of high AS disease activity had new-onset AU during the treatment period.

Conclusions: Results of this prospective open-label study suggest that adalimumab had a substantial preventive effect on AU flares in patients with active AS, including patients with a recent history of AU flares.

Clinical trials: Identifier: NCT00478660.

View Full Text

Statistics from


  • Competing interests: MR, ER, PH and JV were RHAPSODY study investigators. MK and HK are employees of Abbott GmbH & Co KG, an affiliate of Abbott Laboratories. They hold shares of Abbott stock. SK is a contractor of Abbott GmbH.

  • Funding: The research reported here and the preparation of this manuscript were funded by Abbott Laboratories. The RHAPSODY Study Group included experts from academic institutions in Europe and the USA and members of Abbott Laboratories who designed the original clinical trial. Clinical data were collected and analysed by Abbott Laboratories. All authors contributed to manuscript development and reviewed and approved the content of the submitted manuscript.

  • Ethics approval: This study was approved by an independent ethics committee at each centre and all patients provided written, informed consent.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.